Role of Roflumilast Combined with ESHAP Chemotherapy in Relapsed/Refractory Patients with Diffuse Large B-Cell Lymphoma

PURPOSE: There are unmet needs associated with the current treatment strategies for relapsed/refractory diffuse large B-cell lymphoma (DLBCL) due to the poor treatment outcomes of these strategies. Roflumilast, a selective phosphodiesterase-4 inhibitor used for treating chronic obstructive pulmonary...

Descripción completa

Detalles Bibliográficos
Autores principales: Kim, Do Young, Nam, Jehyun, Chung, Joo-seop, Kim, Sang-Woo, Shin, Ho-Jin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Korean Cancer Association 2022
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8756117/
https://www.ncbi.nlm.nih.gov/pubmed/33940789
http://dx.doi.org/10.4143/crt.2020.1371

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8756117/
https://www.ncbi.nlm.nih.gov/pubmed/33940789
http://dx.doi.org/10.4143/crt.2020.1371

Ejemplares similares